Thursday 22 October 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.5%, EPS grew 29.3% and free cash flow fell 52.9%, each against the same quarter a year earlier.
25.90
0.74
+2.94%
Follow XNCR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
11.63 | 9.32 | 9.05 | 5.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.94) | (13.42) | (21.98) | (28.32) | |
P/B ratio |
2.43 | 1.76 | 1.79 | 1.40 | |
Price to Tangible BV |
2.46 | 1.79 | 1.81 | 1.42 | |
EV/Sales |
8.43 | 5.98 | 5.64 | 3.70 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.30) | (3.12) | (5.24) | (4.17) | |
EV/FCF |
(4.23) | (3.07) | (5.09) | (4.03) | |
Quick Ratio |
6.09 | 6.22 | 6.02 | 5.70 | |
Current Ratio |
6.39 | 6.57 | 6.25 | 5.99 | |
Net Debt/EBITDA |
13.18 | 5.91 | 7.85 | 10.48 | |
Debt/Assets |
0.00% | 0.00% | 13.68% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.19 | 0.00 | |
Asset Turnover |
0.13 | 0.12 | 0.14 | 0.16 | |
Operating CF/Net income |
2.56 | 0.52 | 7.77 | 5.11 | |
Capex/Depreciation |
(0.22) | (0.24) | 1.26 | (0.07) | |
Interest Coverage |
(5.04) | (16.57) | (7.29) | (6.20) | |
Research and Development Expense of Revenue |
140.38% | 1,432.00% | 229.57% | 258.90% | |
Selling, General and Administrative Expense of Revenue |
31.99% | 392.14% | 60.35% | 67.39% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
17.95% | 211.71% | 36.07% | 48.06% | |
Graham Net Nets |
0.25 | 0.29 | 0.32 | 0.32 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.48%) | (18.99%) | (8.10%) | (15.09%) | |
Free Cash Flow Yield |
(17.14%) | (20.92%) | (12.25%) | (15.80%) | |
Revenue per Share |
0.68 | 0.06 | 0.38 | 0.28 | |
Operating CF per Share |
(0.73) | (0.90) | (0.70) | (0.41) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.74) | (0.91) | (0.71) | (0.42) | |
Cash per Share |
6.02 | 5.91 | 7.38 | 6.33 | |
Shareholders Equity per Share |
6.63 | 6.85 | 8.56 | 8.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.63 | 6.85 | 8.56 | 8.40 | |
Free Cash Flow |
(56.20) | (68.24) | (52.85) | (31.00) | |
Working Capital |
441.35 | 409.40 | 503.91 | 431.96 | |
Capital Expenditures |
(0.54) | (0.61) | (1.14) | (0.18) | |
Net Current Asset Value |
301.48 | 261.64 | 359.91 | 274.95 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.14 | 0.04 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
44.89 | 24.89 | 45.07 | 23.84 | |
Average Payables |
15.59 | 12.06 | 13.79 | 13.92 | |
Average Assets |
802.19 | 820.77 | 913.72 | 934.36 | |
Average Common Equity |
561.79 | 577.75 | 654.81 | 665.62 |
Columns are period end dates